Drug intelligence / Profile preview

South America spider antivenom

Development stage: Unknown
Lead developer: Inosan Biopharma
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

South America spider antivenom is a polyvalent equine-derived antivenom developed by Inosan Biopharma for the treatment of spider envenomation in South America. The therapeutic consists of F(ab')2 immunoglobulin fragments produced by immunizing horses with venom from clinically significant South American spiders, such as *Loxosceles* (recluse spiders) and *Phoneutria* (armed spiders). These fragments work by binding to and neutralizing the circulating toxins in the venom, preventing them from interacting with their physiological targets and mitigating the systemic and local effects of the bite. It is currently in Phase 1 clinical development.

Other names: South America Spider Antivenom

Beyond the preview

Go deeper on South America spider antivenom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on South America spider antivenom.

Explore the full profile